Cardio-TriTest vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cardio-TriTest

by Cardio-Phoenix Inc.

EchoNext

by Pathway Labs

AI Verdict

Both Cardio-TriTest and EchoNext are AI-powered tools for cardiovascular disease detection, sharing a common specialty in cardiology and family medicine. Cardio-TriTest offers a multi-modal diagnostic approach by combining ECG, PCG, and MCG for comprehensive bio-signal correlation, while EchoNext specializes in analyzing standard ECGs to identify hidden structural heart disease. Therefore, Cardio-TriTest might be preferred for a more comprehensive initial diagnostic workup, whereas EchoNext could be chosen for its focused AI analysis of existing ECG data to detect specific structural conditions.

Choose Cardio-TriTest if…

Choose Cardio-TriTest if your primary care setting requires a comprehensive, multi-modal cardiac assessment device for earlier and more thorough cardiovascular disease detection. This device is ideal for clinicians who benefit from synchronized visual correlation of ECG, PCG, and MCG bio-signals to aid in a broader diagnostic interpretation in a single, non-invasive test. It is particularly well-suited for general practitioners seeking to reduce uncertainty and streamline decision-making regarding heart health.

View Cardio-TriTest →

Choose EchoNext if…

Choose EchoNext if your practice focuses on leveraging AI to analyze standard ECGs for the detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. This tool is best for clinicians who need an FDA-cleared, non-invasive diagnostic support system to identify high-risk patients who may require further echocardiography, thereby expanding access to early heart disease screening. It is designed for broad access, from major hospitals to community practices, and can integrate with existing clinical decision support platforms.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cardio-TriTest	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Clinical setting (device-based)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is deployed through the OpenEvidence clinical decision support platform, which is used by over half of US clinicians, suggesting a streamlined integration into existing workflows. Cardio-TriTest is a device-based solution, which may require additional setup and training for clinical staff.

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy compared to cardiologists in detecting structural heart disease from ECGs, with studies showing it accurately identified 77% of problems compared to 64% for cardiologists. It has also been credited with detecting previously undiagnosed heart failure that led to a heart transplant, highlighting its potential for earlier, life-saving interventions. Cardio-TriTest provides three types of bio-signals as an aid to diagnosis, but specific comparative accuracy or impact on patient outcomes is not detailed in the provided information.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with options for different organizational sizes and an annual discount. Cardio-TriTest requires contacting for pricing, which offers less transparency upfront. While both aim to improve diagnostics, EchoNext's clear pricing structure provides a better understanding of the investment.

Enterprise Readiness

EchoNext

EchoNext is designed for broad access, from major hospitals to community practices, and is available through the OpenEvidence platform, which is widely used by clinicians. It has also been validated in studies across more than 20 hospitals and 500,000 patients in the U.S. and Canada, indicating strong scalability and readiness for enterprise-level deployment. Cardio-TriTest is a device-based solution for clinical settings, but its enterprise readiness is not as clearly articulated.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-cleared AI tool for detecting hidden structural heart disease from standard ECGs, a significant breakthrough in early detection. It leverages deep learning trained on a massive dataset of ECG-echocardiogram pairs to identify conditions often missed by traditional ECG interpretation. Cardio-TriTest combines three bio-signal acquisitions, which is innovative, but EchoNext's specific AI application for hidden disease detection from a common test represents a more impactful innovation in the field.

Support & Docs

Tie

Neither product's provided information or web search results offer specific details about their support services or documentation beyond general statements. Without more information, it's not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cardio-TriTest	EchoNext
Tool Name	Cardio-TriTest	EchoNext
Company	Cardio-Phoenix Inc.	Pathway Labs
Description	AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Diagnostic Capabilities	3-in-1 diagnostic device (ECG, PCG, MCG), Synchronized bio-signal acquisition, Visual correlation of heart bio-signals, AI-powered analysis for heart disease detection	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Cardio-TriTest and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Cardio-TriTest is a device-based solution that combines ECG, PCG, and MCG for synchronized bio-signal acquisition and visual correlation, suggesting it integrates as a point-of-care diagnostic device within a clinical setting. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, which is used by over 500,000 physicians, indicating a software-based integration into existing digital workflows and potentially EHR systems via this platform.

What is the accuracy and sensitivity of each tool in detecting cardiovascular diseases?

EchoNext has demonstrated high accuracy in detecting structural heart disease (SHD), with an AUROC of 85.2% and an AUPRC of 78.5% in internal tests, and 78-80% in external validation. In studies, EchoNext alone achieved 77% accuracy in identifying SHD, outperforming cardiologists who achieved 64% accuracy without AI assistance and 69% with AI assistance. Cardio-TriTest provides synchronized ECG, PCG, and MCG signals for physician interpretation as an aid to diagnosis, but specific accuracy and sensitivity metrics for its AI-powered analysis are not provided in the given information.

What is the learning curve for physicians to effectively use each tool?

The Cardio-TriTest is intended to be used by a physician or trained personnel and provides visually correlated bio-signals to aid diagnosis, suggesting a learning curve associated with interpreting these combined signals. For EchoNext, while not explicitly stated as a 'learning curve' for physicians, its integration into the OpenEvidence platform aims to put its screening output in front of physicians using tools they already utilize, potentially minimizing the need for extensive new software training.

What audit trail features do these tools offer to ensure data integrity and accountability?

The provided information does not explicitly detail the audit trail features for either Cardio-TriTest or EchoNext. Generally, audit trails in clinical research track user identification, timestamps, action details (what was changed or accessed), and are unalterable to ensure data fidelity and transparency.

How do these tools support multi-site rollout and scalability for larger healthcare systems?

Cardio-TriTest is a device-based solution, implying that multi-site rollout would involve deploying physical devices to each location. EchoNext, being available through the OpenEvidence platform, is designed for broad access, from major hospitals to community practices, and has shown robust performance in studies across over 20 hospitals and 500,000 patients in the United States and Canada, suggesting a scalable software-based deployment model.

What specific clinical context or patient populations are these tools best suited for?

Cardio-TriTest is designed for earlier and more comprehensive cardiovascular disease detection in primary care, providing 3-in-1 diagnostic capabilities (ECG, PCG, MCG) for patients aged 20 years and older, excluding pediatrics and intensive care units. EchoNext is an AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, making it suitable for broad screening in various settings to identify patients who should proceed to an echocardiogram.